Promising cholesterol drugs from Sanofi, Regeneron, Amgen, Pfizer face scrutiny
This article was originally published in Scrip
Executive Summary
Questions about future drug approvals are surfacing as Sanofi, Regeneron Pharmaceuticals, Amgen and others chase a potential multi-billion dollar market that improves upon standard cholesterol-lowering medicines and helps millions of people who are difficult to treat.